Travere Therapeutics (TVTX) Other Non Operating Income (2013 - 2026)
Travere Therapeutics posted quarterly Other Non Operating Income of -$91000.0 for Q1 2026, down 116.58% year-on-year from $549000.0 in Q1 2025, and down 100.82% on a QoQ basis from $11.1 million in Q4 2025.
Travere Therapeutics (TVTX) has 14 years of Other Non Operating Income data on file, last reported at -$91000.0 in Q1 2026.
- For the quarter ending Q1 2026, Other Non Operating Income fell 116.58% year-over-year to -$91000.0; the trailing twelve-month figure through Mar 2026 stood at $10.9 million (up 463.72% YoY), and the FY2025 full-year result was $11.6 million, up 448.95% from the prior year.
- Other Non Operating Income for Q1 2026 stood at -$91000.0, down from $11.1 million in the prior quarter.
- Across five years, Other Non Operating Income topped out at $11.1 million in Q4 2025 and bottomed at -$3.5 million in Q2 2024.
- The 5-year median for Other Non Operating Income is $56500.0 (2022), against an average of $573812.5.
- The widest annual swing landed in 2023, when Other Non Operating Income jumped 6345.45%; it then slumped 1638.81% in 2024.
- A 5-year view of Other Non Operating Income shows it stood at -$22000.0 in 2022, then surged by 6345.45% to $1.4 million in 2023, then sank by 142.29% to -$581000.0 in 2024, then surged by 2004.82% to $11.1 million in 2025, then plunged by 100.82% to -$91000.0 in 2026.
- The last three Other Non Operating Income figures came in at -$91000.0 (Q1 2026), $11.1 million (Q4 2025), and $487000.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn |
| 10 | Travere Therapeutics | 4.34 Bn | 4.26 Bn | 102.38 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -91,000.00 |
| Dec 31, 2025 | 11.07 Mn |
| Sep 30, 2025 | 487,000.00 |
| Jun 30, 2025 | -526,000.00 |
| Mar 31, 2025 | 549,000.00 |
| Dec 31, 2024 | -581,000.00 |
| Sep 30, 2024 | 520,000.00 |
| Jun 30, 2024 | -3.50 Mn |
| Mar 31, 2024 | 238,000.00 |
| Dec 31, 2023 | 1.37 Mn |
| Sep 30, 2023 | 335,000.00 |
| Jun 30, 2023 | -201,000.00 |
| Mar 31, 2023 | 87,000.00 |
| Dec 31, 2022 | -22,000.00 |
| Sep 30, 2022 | -586,000.00 |
| Mar 31, 2022 | 26,000.00 |
| Dec 31, 2021 | -1.09 Mn |
| Sep 30, 2021 | 654,000.00 |
| Dec 31, 2020 | 620,000.00 |
| Sep 30, 2020 | -564,000.00 |
| Jun 30, 2020 | -247,000.00 |
| Mar 31, 2020 | 191,000.00 |
| Dec 31, 2019 | 359,000.00 |
| Sep 30, 2019 | 315,000.00 |
| Jun 30, 2019 | 125,000.00 |
| Mar 31, 2019 | 117,000.00 |
| Dec 31, 2018 | -17.07 Mn |
| Sep 30, 2018 | -17.00 Mn |
| Jun 30, 2018 | -403,000.00 |
| Mar 31, 2018 | 121,000.00 |
| Dec 31, 2017 | 1.47 Mn |
| Sep 30, 2017 | 557,000.00 |
| Jun 30, 2017 | 382,000.00 |
| Mar 31, 2017 | -76,000.00 |
| Dec 31, 2016 | -19,000.00 |
| Sep 30, 2016 | 151,000.00 |
| Jun 30, 2016 | 71,000.00 |
| Mar 31, 2016 | -69,000.00 |
| Dec 31, 2015 | 2.21 Mn |
| Sep 30, 2015 | -314,000.00 |
| Jun 30, 2015 | 522,000.00 |
| Mar 31, 2015 | 23,000.00 |
| Dec 31, 2014 | -10.33 Mn |
| Sep 30, 2014 | 3.89 Mn |
| Jun 30, 2014 | 26.46 Mn |
| Mar 31, 2014 | -53.61 Mn |
| Dec 31, 2013 | -874,299.00 |
| Sep 30, 2013 | -6.04 Mn |
| Jun 30, 2013 | 61,389.00 |
| Mar 31, 2013 | -2.98 Mn |